{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=9",
    "query": {
      "condition": "Ovary Disease",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 2268,
    "total_pages": 227,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T19:39:20.983Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00093626",
      "title": "Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Peritoneal Carcinoma",
        "Recurrent Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 73,
      "start_date": "2004-10",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00093626"
    },
    {
      "nct_id": "NCT04575935",
      "title": "Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Ovarian Carcinoma",
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Tumor",
        "Fallopian Tube Serous Neoplasm",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Primary Peritoneal Clear Cell Adenocarcinoma",
        "Primary Peritoneal Endometrioid Adenocarcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Primary Peritoneal Transitional Cell Carcinoma",
        "Stage IIIC Fallopian Tube Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Primary Peritoneal Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Laparotomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Minimally Invasive Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 580,
      "start_date": "2020-08-05",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 13,
      "location_summary": "Miami, Florida • Weston, Florida • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04575935"
    },
    {
      "nct_id": "NCT01188876",
      "title": "Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "pralatrexate",
          "type": "DRUG"
        },
        {
          "name": "Folic Acid",
          "type": "DRUG"
        },
        {
          "name": "Vitamin B12 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2010-08",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2018-01-19",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188876"
    },
    {
      "nct_id": "NCT03398655",
      "title": "A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Platinum Resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "VB-111 + Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo + Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vascular Biogenics Ltd. operating as VBL Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 408,
      "start_date": "2017-12-19",
      "completion_date": "2022-07-19",
      "has_results": false,
      "last_update_posted_date": "2023-01-10",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03398655"
    },
    {
      "nct_id": "NCT03206216",
      "title": "Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Burning Pain",
        "Impaired Balance",
        "Malignant Ovarian Neoplasm",
        "Numbness",
        "Peripheral Neuropathy",
        "Pain, Acute",
        "Tingling"
      ],
      "interventions": [
        {
          "name": "Diode Laser fiber type Selective Stimulator (DLss)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2017-08-04",
      "completion_date": "2017-10-30",
      "has_results": true,
      "last_update_posted_date": "2018-12-19",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03206216"
    },
    {
      "nct_id": "NCT01422733",
      "title": "Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hyperandrogenemia",
        "Obesity",
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Cosyntropin",
          "type": "DRUG"
        },
        {
          "name": "rhCG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "16 Years",
        "sex": "FEMALE",
        "summary": "7 Years to 16 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2018-06-01",
      "completion_date": "2018-07-17",
      "has_results": false,
      "last_update_posted_date": "2018-07-19",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422733"
    },
    {
      "nct_id": "NCT00055432",
      "title": "Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Gemzar and Alimta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-09-15",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055432"
    },
    {
      "nct_id": "NCT01199263",
      "title": "Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pelareorep",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 108,
      "start_date": "2010-12-06",
      "completion_date": "2020-07-17",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 36,
      "location_summary": "Burbank, California • Mountain View, California • Hartford, Connecticut + 30 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01199263"
    },
    {
      "nct_id": "NCT05870748",
      "title": "REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer",
        "Platinum-resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Luveltamab tazevibulin",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2023-07-12",
      "completion_date": "2025-08-26",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 37,
      "location_summary": "Tucson, Arizona • Daly City, California • San Diego, California + 33 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05870748"
    },
    {
      "nct_id": "NCT00944944",
      "title": "Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer",
        "Uterine Cancer",
        "Vaginal Cancer",
        "Lymphedema"
      ],
      "interventions": [
        {
          "name": "limb volume measurements and GCLQ lymphedema symptom assessment questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "GCLQ lymphedema symptom assessment questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2009-07",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2010-02-01",
      "last_synced_at": "2026-10-21T19:39:20.983Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00944944"
    }
  ]
}